Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

European phase II study of 20 patients reported in Annals of Oncology

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication, by two European institutions, of results of a limited phase II study of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by administration of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60 years of age or older) with previously untreated diffuse large B-cell lymphoma (DLBCL). In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks later. The study, which had an overall response rate (ORR) of 100 percent, including a 95 percent complete remission (CR) rate, indicated the efficacy, tolerability, and feasibility of this regimen for these patients. Results of the study were reported in the online edition of February 2008 Annals of Oncology. CTI acquired the U.S. rights to Zevalin in December, 2007.

"Although a small phase II experience, these results in elderly lymphoma patients treated with Zevalin following CHOP without rituximab demonstrate high rates of complete remissions and overall survival and are consistent with the potential to use Zevalin as consolidation therapy in aggressive lymphoma," noted Jack W. Singer, M.D., Chief Medical Officer of CTI. "We continue to be impressed with the high rate of conversion of partial to complete remissions following Zevalin consolidation irrespective of whether or not rituximab therapy is utilized. This publication demonstrates this in elderly patients with DLBCL while similar data in indolent lymphomas were reported at ASH 2007 fr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... New York, NY (PRWEB) August 28, 2014 ... has renewed its long term partnership with PTI ... to provide clients with state of the art leak ... state of the art instruments currently available. As part ... a new High Voltage Leak Detection Instrument ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 ... $6 million in Series B funding and secured Otter ... and investment capital will accelerate commercialization of GGI’s Agriplier™ ... multiple crop types. , “Since our first meeting, ... commitment to the biological product space,” said Alan Sobba, ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... Force, a web based CTMS (Clinical Trial Management ... selected and deployed Clinical Force to manage worldwide ... Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site ... Future phases of our project will include integration ...
... Inc. (Nasdaq: IDIX ) announced today that management ... programs at the Canaccord Adams Hepatitis C Conference on Tuesday, ... Barclay New York Hotel in New York City.The live and ... of Events" in the Idenix Investor Center at ...
... YORK, April 3 /PRNewswire-Asia-FirstCall/ -- China Agri-Business, Inc.,(OTC ... products through its operating company in China, announced ... , Revenue for the ... of 3.8% as compared to $3,037,414 for the ...
Cached Biology Technology:Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS 2Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS 3China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2Yale study identifies possible bacterial drivers of IBD 2
... A team of Howard Hughes Medical Institute (HHMI) scientists has ... able to turn off genes selectively to control critical events ... molecular images of the structure of Dicer, an enzyme that ... which is reported in the January 13, 2005, issue of ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... regenerative medicine, researchers at Rice University have discovered a new ... that the cells themselves produce a growth matrix that is ... appears online this week in the Proceedings of the National ... science ?researchers found they could coax bone cells into produce ...
Cached Biology News:Molecule does more than slice and dice RNA 2Molecule does more than slice and dice RNA 3Molecule does more than slice and dice RNA 4USC, Rice to develop bacteria-powered fuel cells 2Findings advance use of adult stem cells for replacement bone 2
... a chemically modified form of AmpliTaq® DNA ... to the enzyme, the enzyme is inactive. ... thermal cycling (when the reaction is going ... inactive. The result is that mis-primed primers ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: